Selective FGFR1 and FGFR3 inhibitor (IC50 values are 5, 21.5, ~100, 17600 and 19800 nM for FGFR3, FGFR1, VEGFR2, PDGFR and c-Src respectively, and > 50000 nM for EGFR, InsR, MEK and PKC). Inhibits VEGF- and FGF-induced angiogenesis in the mouse cornea model of angiogenesis. Inhibits proliferation and differentiation of oligodendrocyte progenitors. Suppresses cell proliferation in cell lines expressing mutated FGFR3 protein. Blocks tumor growth in H510 and H69 SCLC xenograft models.
Sold for research purposes under agreement from Pfizer Inc.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 523.67. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.91 mL||9.55 mL||19.1 mL|
|5 mM||0.38 mL||1.91 mL||3.82 mL|
|10 mM||0.19 mL||0.95 mL||1.91 mL|
|50 mM||0.04 mL||0.19 mL||0.38 mL|
References are publications that support the products' biological activity.
Bansal et al (2003) Specific inhibitor of FGF receptor signaling: FGF-2-mediated effects on proliferation, differentiation, and MAPK activation are inhibited by PD173074 in oligodendrocyte-lineage cells. J.Neurosci.Res. 74 486 PMID: 14598292
Miyake et al (2010) 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bla J.Pharmacol.Exp.Ther. 332 795 PMID: 19955487
If you know of a relevant reference for PD 173074, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: PD 173074, supplier, Selective, FGFR1, FGFR3, inhibitors, inhibits, fibroblast, growth, factors, PD173074, stem, cells, Pfizer, FGFR, Stem, Cell, Proliferation, Neural, Stem, Cells, FGFR, Tocris Bioscience
15 Citations for PD 173074
Citations are publications that use Tocris products. Selected citations for PD 173074 include:
MacKenzie et al (2015) Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis. Respir Res 16 83 PMID: 26138239
Saito et al (2015) The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma. BMC Cancer 15 82 PMID: 25884729
Witty et al (2014) Generation of the epicardial lineage from human pluripotent stem cells. Nat Biotechnol 32 1026 PMID: 25240927
Gibson et al (2012) Activation of glial FGFRs is essential in glial migration, proliferation, and survival and in glia-neuron signaling during olfactory system development. PLoS One 7 e33828 PMID: 22493675
Wilson et al (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487 505 PMID: 22763448
Borroto-Escuela et al (2012) The existence of FGFR1-5-HT1A receptor heterocomplexes in midbrain 5-HT neurons of the rat: relevance for neuroplasticity. J Neurosci 32 6295 PMID: 22553035
Shifley et al (2012) Prolonged FGF signaling is necessary for lung and liver induction in Xenopus. BMC Dev Biol 12 27 PMID: 22988910
Knuchel et al (2015) Fibroblast surface-associated FGF-2 promotes contact-dependent colorectal cancer cell migration and invasion through FGFR-SRC signaling and integrin αvβ5-mediated adhesion. Development 6 14300 PMID: 25973543
Benzina et al (2015) A kinome-targeted RNAi-based screen links FGF signaling to H2AX phosphorylation in response to radiation. Stem Cells Int 72 3559 PMID: 25894690
Yang et al (2015) Inhibition of G9a Histone Methyltransferase Converts Bone Marrow Mesenchymal Stem Cells to Cardiac Competent Progenitors. Dev Dyn 2015 270428 PMID: 26089912
Rankin et al (2015) A Molecular atlas of Xenopus respiratory system development. PLoS One 244 69 PMID: 25156440
Anreddy et al (2014) PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR. Development 4 202 PMID: 26579384
Rankin et al (2012) Suppression of Bmp4 signaling by the zinc-finger repressors Osr1 and Osr2 is required for Wnt/β-catenin-mediated lung specification in Xenopus. Cell Mol Life Sci 139 3010 PMID: 22791896
Rodríguez et al (2012) Modulation of pluripotency in the porcine embryo and iPS cells. Acta Pharm Sin B 7 e49079 PMID: 23145076
Cho et al (2012) Conversion from mouse embryonic to extra-embryonic endoderm stem cells reveals distinct differentiation capacities of pluripotent stem cell states. J Biol Chem 139 2866 PMID: 22791892
Do you know of a great paper that uses PD 173074 from Tocris? If so please let us know.
Reviews for PD 173074
There are currently no reviews for this product. Be the first to review PD 173074 and earn rewards!
Have you used PD 173074?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Stem Cells Scientific Review
Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.